共查询到20条相似文献,搜索用时 15 毫秒
1.
2.
3.
Van As FM 《The Canadian veterinary journal. La revue veterinaire canadienne》2002,43(12):908-908; author reply 911
4.
5.
6.
The objective of the study was to assess the efficacy of different prophylactically applied homeopathic compounds on health and fertility during the periparturient period on an organic dairy farm. In a randomised double blinded study 146 dairy cows were enrolled in two treatment groups.The average milk yield was about 5100 kg per cow per lactation. The treatment group received the homeopathic compounds Carduus comp. and Coenzyme comp. at drying off, Traumeel on the day of calving, Lachesis comp. on day 7 post partum (p.p.) and Carduus comp. and Coenzyme comp. on day 14 days p.p. The control group followed the same protocol with a placebo (physiological saline solution). Each drug was administered subcutaneously in a dosage of 5 ml. At drying off, the day of calving and in weekly intervals until day 35 p.p. clinical examinations as well as blood sampling were performed. The effect of treatment was measured by clinical parameters, reproductive performance and serum profiles (Ca, P, AST, Urea, Bilirubin). Data of reproductive performance (days to first service, days open, conception rate) were compared between treatment groups and to those in the previous lactation. There was no significant difference between both treatment groups. Cows of the treatment group had an earlier onset of cyclic activity, especially when milk yield was considered as an influencing factor (82% vs. 57%, P < 0,05). In contrast the cows of the treatment group had a significant lower submission rate. The prophylactic treatment of all cows did not have an effect in general, but in cows with increased milk yield, especially in the current lactation. The reproductive performance in the previous lactation did not have any effects on the success of the homeopathic treatment. Reproductive performance in the herd could be enhanced slightly compared to the previous lactation. 相似文献
7.
8.
9.
10.
《中国动物保健》2005,(7)
芬兰芬恩制药公司(Orion Pharma)和辉瑞公司(Pfizer)已经延长了它们在镇静药和镇痛药领域内的市场合作与发展协议,虽然协议的金额未公布,但双方都肯定这将会促进彼此的发展。辉瑞公司称它与芬恩的协议是以两公司间已经存在的合作为基础的。辉瑞已经在美国和大部分欧洲市场成功的经销芬恩的动物镇静剂家族系列产品,包括Domosedan(地托咪定,10mg/ml),Domitor(美托咪定)和Antisedan,辉瑞决定在大部分亚洲国家(包括中国和泰国),拉丁美洲,中东市场上继续销售这些产品。Domosedan适用于马类与牛类临床检查,小型手术术前麻醉相关的镇痛与镇静之… 相似文献
11.
英特威公司在欧洲的疫苗销售CVMP对英特威公司的疫苗Nobivac Piro上市采取了积极的态度。这种疫苗包括两种可溶性寄生虫抗原犬巴贝斯虫和俄罗斯巴贝斯虫,对犬的巴贝斯虫有免疫活性。该公司还在法国上市了Bovilis IBR疫苗,这是一种单联的牛用疫苗,对传染性牛鼻气管炎有保护作用。Bovilis IBR在其它一些欧洲国家早已上市。英特威英国公司宣布扩展了其犬疫苗Nobivac DHPPi的使用间隔。这家英国公司是第一个建议事主用Nobivac DHPPi保护犬免受细小病毒、肝炎病毒和犬瘟热病毒感染的公司,保护期为三年。礼来公司的产品Micotil 300在法… 相似文献
12.
13.
14.
15.
16.
17.
18.
19.
20.